EFFECT OF INTRAVENOUS DOSE AND SCHEDULE ON CEREBROSPINAL-FLUID PHARMACOKINETICS OF 5-FLUOROURACIL IN THE MONKEY
- 1 January 1984
- journal article
- research article
- Vol. 44 (11) , 4929-4932
Abstract
There is little information regarding the pharmacology of 5-fluorouracil (5-FUra) in the CNS, despite its role in the treatment of diseases with CNS metastases and recent reports of neurotoxicity. In this study, the plasma and CSF pharmacokinetics of 5-UFra were examined in a primate model. Following a bolus dose, the area under the concentration vs. time curves for 5-FUra in CSF was 48% of the plasma area under the concentration vs. time curves. For continuous infusion of 5-FUra, the area under the concentration vs. time curves ratio for CSF:plasma was 20 or 11%, depending upon the infusion rate. The mechanism for variations in CSF exposure based upon the pattern of plasma delivery is consistent with local metabolism of 5-FUra in the CNS. These findings should be considered in the evaluation of delivery schedules which are intended to maximize drug delivery to the CNS and/or minimize neurotoxicity.This publication has 5 references indexed in Scilit:
- Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patientsCancer, 1982
- HIGH-DOSE ALLOPURINOL MODULATION OF 5-FU TOXICITY - PHASE-I TRIAL OF AN OUTPATIENT DOSE SCHEDULE1982
- Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routesClinical Pharmacology & Therapeutics, 1980
- A sensitive method for determination of 5-fluorouracil and 5-fluoro-2′-deoxyuridine in human plasma by high-pressure liquid chromatographyAnalytical Biochemistry, 1980
- The physiologic disposition of 5‐fluorouracil and 5‐fluoro‐2′‐deoxyuridine in manClinical Pharmacology & Therapeutics, 1964